The introduction of new sensitive assays for the detection of HLA antibodies on basis of their binding to isolated HLA molecules has got an enormous impact on the decision-making process with respect to donor selection for sensitized patients. In the past, when only complement-dependent cytotoxicity was used as a tool to define HLA alloantibodies, the presence of donor specific antibodies (DSA) before transplantation was considered a contraindication for renal transplantation with that donor. The interpretation of the current DSA results is far more difficult and leads to a lot of discussions and controversy. The problems associated with the use of solid phase assays for clinical decision making and possible solutions are discussed. © 2012 The Authors. Transplant International © 2012 European Society for Organ Transplantation.
CITATION STYLE
Roelen, D. L., Doxiadis, I. I. N., & Claas, F. H. J. (2012). Detection and clinical relevance of donor specific HLA antibodies: A matter of debate. In Transplant International (Vol. 25, pp. 604–610). https://doi.org/10.1111/j.1432-2277.2012.01491.x
Mendeley helps you to discover research relevant for your work.